#1 Clinical Trials Search in Europe

Human Igg1 Monoclonal Antibody Against Fucosyl-Gm1

This article discusses ongoing clinical trials investigating the use of Human IgG1 Monoclonal Antibody Against Fucosyl-GM1 (BMS-986012) in the treatment of extensive-stage small cell lung cancer (SCLC). These trials aim to evaluate the safety, efficacy, and potential benefits of combining this novel drug with standard chemotherapy regimens for patients with this aggressive form of lung cancer.

Table of Contents

What is Human IgG1 Monoclonal Antibody Against Fucosyl-GM1?

Human IgG1 Monoclonal Antibody Against Fucosyl-GM1, also known by its sponsor product code BMS986012, is an innovative medication currently being studied for the treatment of cancer[1][2]. This drug is a type of monoclonal antibody, which is a laboratory-created protein designed to target specific cells in the body. In this case, it targets a molecule called Fucosyl-GM1, which is found on certain cancer cells.

What Condition Does It Target?

The primary focus of current clinical trials for this medication is extensive-stage small cell lung cancer (ES-SCLC)[1][2]. Small cell lung cancer is an aggressive form of lung cancer that often spreads quickly to other parts of the body. When it has spread beyond the lungs, it is referred to as “extensive-stage.” This condition is particularly challenging to treat, making new therapies like BMS986012 potentially valuable additions to the treatment arsenal.

How Does It Work?

While the exact mechanism of action is not fully detailed in the provided information, monoclonal antibodies generally work by targeting specific molecules on cancer cells. In this case, the antibody targets Fucosyl-GM1, which is likely present on small cell lung cancer cells. By attaching to these molecules, the antibody may help the immune system identify and attack the cancer cells more effectively[1][2].

Current Clinical Trials

BMS986012 is currently being evaluated in clinical trials to assess its safety and effectiveness. Two notable trials are:

  1. A Phase 2 trial combining BMS986012 with carboplatin, etoposide, and nivolumab for first-line treatment of ES-SCLC[1].
  2. A Phase 1/2 trial testing BMS986012 in combination with platinum-based chemotherapy (cisplatin/etoposide or carboplatin/etoposide) for first-line therapy in ES-SCLC[2].
These trials aim to determine if adding BMS986012 to standard chemotherapy regimens can improve outcomes for patients with ES-SCLC.

How Is It Administered?

BMS986012 is administered as a solution for injection through intravenous use, meaning it is given directly into a vein[1][2]. This method allows the medication to enter the bloodstream quickly and circulate throughout the body to reach cancer cells.

Combination Therapy

In the ongoing clinical trials, BMS986012 is being tested in combination with other cancer treatments:

  • Carboplatin and etoposide: These are chemotherapy drugs commonly used to treat small cell lung cancer[1][2].
  • Nivolumab: This is an immunotherapy drug that helps the immune system fight cancer cells[1].
  • Cisplatin: Another chemotherapy drug used in some trial arms[2].
The combination approach aims to attack cancer cells through multiple mechanisms, potentially improving treatment effectiveness.

Potential Side Effects and Safety Considerations

As with any medical treatment, there may be side effects and safety concerns. The clinical trials are closely monitoring for:

  • Adverse events (AEs) and serious adverse events (SAEs)[1][2]
  • Events leading to treatment discontinuation[1][2]
  • Any deaths related to treatment[1][2]
  • Changes in laboratory test results[2]
It’s important to note that the full safety profile of BMS986012 is still being established through these trials.

Who Might Be Eligible for Treatment?

While eligibility criteria may vary between trials, some common factors include:

  • Diagnosed with extensive-stage small cell lung cancer[1][2]
  • Age 18 or older[2]
  • Good overall health status (ECOG performance status of 0 or 1)[1][2]
  • No prior systemic therapy for lung cancer[2]
  • No active brain metastases or certain other health conditions[2]
Always consult with a healthcare provider to determine if you might be eligible for a clinical trial or treatment.

Future Prospects and Ongoing Research

The ongoing clinical trials are evaluating several important aspects of BMS986012:

  • Its effectiveness in improving progression-free survival (PFS) and overall survival (OS)[1][2]
  • How the body processes the drug (pharmacokinetics)[2]
  • The body’s immune response to the drug (immunogenicity)[1][2]
  • Its effectiveness when combined with other cancer treatments[1][2]
The results of these trials will help determine the future role of BMS986012 in treating extensive-stage small cell lung cancer and potentially other conditions.

Aspect Details
Drug Name Human IgG1 Monoclonal Antibody Against Fucosyl-GM1 (BMS-986012)
Condition Studied Extensive-stage Small Cell Lung Cancer (SCLC)
Trial Phases Phase 1/2 and Phase 2
Combination Therapy BMS-986012 with carboplatin, etoposide, and nivolumab
Primary Objectives Assess safety, tolerability, and efficacy (Progression-Free Survival)
Secondary Objectives Evaluate overall survival, response rates, and immunogenicity
Key Eligibility Criteria Adults with extensive-stage SCLC, ECOG status 0-1, no prior systemic therapy
Main Exclusion Criteria Active brain metastases, other active malignancies, certain autoimmune diseases
Administration Route Intravenous use

FAQ

  • What is Human IgG1 Monoclonal Antibody Against Fucosyl-GM1? Human IgG1 Monoclonal Antibody Against Fucosyl-GM1, also known as BMS-986012, is a new drug being studied for the treatment of extensive-stage small cell lung cancer. It is a type of targeted therapy that aims to attack specific cancer cells.
  • What is the main goal of these clinical trials? The main goals of these trials are to assess the safety and effectiveness of BMS-986012 when combined with standard chemotherapy drugs like carboplatin and etoposide. They also aim to determine if adding BMS-986012 to the treatment regimen can improve outcomes for patients with extensive-stage small cell lung cancer.
  • Who is eligible to participate in these clinical trials? Eligible participants are adults (18 years or older) with extensive-stage small cell lung cancer who have not received prior systemic therapy. They must have measurable disease and be in relatively good health with an ECOG performance status of 0 or 1.
  • What are the potential benefits of participating in these trials? Participants may benefit from receiving a new, potentially more effective treatment for their cancer. The trials also contribute to the advancement of cancer research, which may help future patients. However, it's important to note that there are also risks involved, and the effectiveness of the new treatment is not guaranteed.
  • How long do these clinical trials last? The duration of the trials varies, but typically involves an initial treatment phase of 4 cycles (about 12 weeks) followed by a maintenance phase. Participants may continue receiving the study drug until their disease progresses or they experience unacceptable side effects.

Ongoing Clinical Trials on Human Igg1 Monoclonal Antibody Against Fucosyl-Gm1

  • Study of BMS-986012 with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Greece Italy The Netherlands Poland Romania +1

Glossary

  • Extensive-stage Small Cell Lung Cancer (SCLC): A type of lung cancer that has spread beyond the lung where it started and to other parts of the body. It is characterized by rapid growth and spread.
  • Human IgG1 Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. It is designed to target and attach to a specific antigen on cancer cells.
  • Fucosyl-GM1: A specific molecule found on the surface of some cancer cells, particularly in small cell lung cancer, which is targeted by the antibody BMS-986012.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Blinded Independent Central Review (BICR): A method used in clinical trials where independent experts review data without knowing which treatment a patient received, to ensure unbiased assessment.

References

  1. http://clinicaltrials.eu/trial/study-of-bms-986012-with-carboplatin-etoposide-and-nivolumab-for-first-line-treatment-in-patients-with-extensive-stage-small-cell-lung-cancer/
  2. http://clinicaltrials.eu/trial/study-of-bms-986012-with-chemotherapy-for-patients-with-extensive-stage-small-cell-lung-cancer/